Arvinas logo

ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study

Sara A. Hurvitz, et al.

December 6, 2022
San Antonio Breast Cancer Symposium
Skip to content